Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 12, 2014, Pages 4578-4583

  Heiman, Myriam ^a,b,c,d   Heilbut, Adrian ^d,e   Francardo, Veronica ^f   Kulicke, Ruth ^a,b,c,d   Fenster, Robert J ^a,b,c,d,i   Kolaczyk, Eric D ^e,g   Mesirov, Jill P ^d,e   Surmeier, Dalton J ^h   Cenci, M Angela ^f   Greengard, Paul ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c The Picower Institute for Learning and Memory   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e BOSTON UNIVERSITY   (United States)

^f Boston University   (United States)

^g LUND UNIVERSITY   (Sweden)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL TYPE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DYSKINESIA; GENE EXPRESSION; MOLECULAR DYNAMICS; MOUSE; NERVE CELL; NERVE PROJECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPINY PROJECTION NEURON;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DYSKINESIA, DRUG-INDUCED; GENE EXPRESSION; HOMEOSTASIS; LEVODOPA; MICE;

EID: 84897010488     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1401819111     Document Type: Article

References (41)

1. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318(14):876-880. (Pubitemid 18090271)
2. Gerfen CR, Surmeier DJ (2011) Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34:441-466.
3. Nutt JG (1990) Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology 40(2):340-345.
4. Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20(2):190-199. (Pubitemid 40361122)
5. Cenci MA, Lee CS, Björklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10(8):2694-2706. (Pubitemid 28362576)
6. Aubert I, et al. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57(1):17-26. (Pubitemid 40053311)
7. Santini E, et al. (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27(26):6995-7005. (Pubitemid 47015907)
8. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA- induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62(7):800-810. (Pubitemid 47374647)
9. Nicholas AP, et al. (2008) Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem 106(1):486-494. (Pubitemid 351840228)
10. Santini E, Heiman M, Greengard P, Valjent E, Fisone G (2009) Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal 2(80):ra36.
11. Crittenden JR, et al. (2009) Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proc Natl Acad Sci USA 106(8):2892-2896.
12. Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 66(6):603-613.
13. Cenci MA, Konradi C (2010) Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 183:209-233.
14. Luquin MR, Laguna J, Obeso JA (1992) Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 31(5):551-554.
15. Grondin R, Doan VD, Grégoire L, Bédard PJ (1999) D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 52(4):771-776. (Pubitemid 29120183)
16. Monville C, Torres EM, Dunnett SB (2005) Validation of the L-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res Bull 68(1-2):16-23. (Pubitemid 41698872)
17. Gold SJ, et al. (2007) RGS9-2 negatively modulates L-3,4- dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci 27(52):14338-14348.
18. Lindgren HS, Ohlin KE, Cenci MA (2009) Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 34(12):2477-2488.
19. Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: Relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16(1):110-123. (Pubitemid 38569802)
20. Francardo V, et al. (2011) Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol Dis 42(3):327-340.
21. Heiman M, et al. (2008) A translational profiling approach for the molecular characterization of CNS cell types. Cell 135(4):738-748.
22. Huang CY, Tan TH (2012) DUSPs, to MAP kinases and beyond. Cell Biosci 2(1):24.
23. Gerfen CR, Miyachi S, Paletzki R, Brown P (2002) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22(12):5042-5054. (Pubitemid 37465618)
24. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30(5):236-243. (Pubitemid 46654236)
25. Lundblad M, et al. (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194(1):66-75. (Pubitemid 40719744)
26. Patterson KI, Brummer T, O'Brien PM, Daly RJ (2009) Dual-specificity phosphatases: Critical regulators with diverse cellular targets. Biochem J 418(3):475-489.
27. Pachkov M, Balwierz PJ, Arnold P, Ozonov E, van Nimwegen E (2013) SwissRegulon, a database of genome-wide annotations of regulatory sites: Recent updates. Nucleic Acids Res 41(Database issue):D214-D220.
28. Cantuti-Castelvetri I, et al. (2010) Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats. PLoS ONE 5(11):e13861.
29. Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6(6):461-474. (Pubitemid 30036616)
30. Letourneux C, Rocher G, Porteu F (2006) B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J 25(4):727-738. (Pubitemid 43292435)
31. Gao M, et al. (2004) Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 306(5694):271-275. (Pubitemid 39336871)
32. Warren OC, et al. (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 28(8):1064-1071.
33. Greengard P (2001) The neurobiology of slow synaptic transmission. Science 294(5544):1024-1030.
34. Posner BA, Gilman AG, Harris BA (1999) Regulators of G protein signaling 6 and 7. Purification of complexes with gbeta5 and assessment of their effects on G protein-mediated signaling pathways. J Biol Chem 274(43):31087-31093.
35. Druey KM, et al. (1999) Amino-terminal cysteine residues of RGS16 are required for palmitoylation and modulation of Gi- and Gq-mediated signaling. J Biol Chem 274(26):18836-18842.
36. Hopf FW, Seif T, Mohamedi ML, Chen BT, Bonci A (2010) The small-conductance calcium-activated potassium channel is a key modulator of firing and long-term depression in the dorsal striatum. Eur J Neurosci 31(11):1946-1959.
37. Młyniec K, Budziszewska B, Reczyński W, Sowa-Kućma M, Nowak G (2013) The role of the GPR39 receptor in zinc deficient-animal model of depression. Behav Brain Res 238:30-35.
38. Młyniec K, Nowak G (2013) GPR39 up-regulation after selective antidepressants. Neurochem Int 62(7):936-939.
39. Perlmann T, Wallén-Mackenzie A (2004) Nurr1, an orphan nuclear receptor with essential functions in developing dopamine cells. Cell Tissue Res 318(1):45-52. (Pubitemid 39366053)
40. Jankovic J, Chen S, Le WD (2005) The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 77(1-2):128-138. (Pubitemid 41654775)
41. Ferreira JJ, Rascol O (2000) Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Curr Opin Neurol 13(4):431-436.